{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:11:36Z","timestamp":1761581496641},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jviromet.2016.12.008","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T03:47:06Z","timestamp":1481860026000},"page":"41-45","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes"],"prefix":"10.1016","volume":"241","author":[{"given":"Carole L","family":"Wallis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel V","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanmugam","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Silva de Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias K","family":"Halvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2016.12.008_bib0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350701200508","article-title":"Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort","volume":"12","author":"Boulle","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2016.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(07)60571-6","article-title":"Raltegravir: a new antiretroviral class for salvage therapy","volume":"369","author":"Cahn","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0020","first-page":"11","article-title":"Expanded access drug profile: raltegravir (RAL, MK-0518)","volume":"19","author":"Colquitt","year":"2007","journal-title":"Hopkins HIV Rep."},{"key":"10.1016\/j.jviromet.2016.12.008_bib0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00126334-200311010-00006","article-title":"MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an Adult AIDS Clinical Trials Group study","volume":"34","author":"Haas","year":"2003","journal-title":"J. Acquired Immune Deficiency Syndromes (1999)"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0035","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS (London England)"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0040","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.jviromet.2016.12.008_bib0045","series-title":"AIDS by the Numbers","first-page":"2015","author":"UNAIDS","year":"2015"},{"key":"10.1016\/j.jviromet.2016.12.008_bib0050","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","article-title":"Five antiretroviral drug class-Resistant HIV-1 in a treatment-Naive patient successfully suppressed with optimized antiretroviral drug selection","volume":"14","author":"Volpe","year":"2015","journal-title":"J. Int. Assoc. Providers AIDS Care"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416303597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416303597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T08:24:40Z","timestamp":1658046280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093416303597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":10,"alternative-id":["S0166093416303597"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.12.008","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}